Biocon Biologics Ltd said on Tuesday its subsidiary had secured a three-year contract from the Malaysian government worth $90 million (approximately Rs 688 crore) to supply the recombinant human insulin brand Insugen. Biocon Sdn Bhd has been awarded a three-year contract by the Ministry of Health Malaysia (MoH).

Biocon Sdn Bhd, a subsidiary of Biocon Biologics Malaysia, will manufacture and supply its insulin range to its partner Duopharma Marketing Sdn Bhd (DMktg). DMktg is a subsidiary of Duopharma Biotech, a leading pharmaceutical and biotech company in Malaysia. We are delighted to renew our commitment to provide affordable recombinant human insulin to people with diabetes in Malaysia through this new government contract.

This will enable us to serve more than 400,000 people with diabetes using recombinant human insulin, helping governments achieve equitable access to diabetes care,” said Susheel Umesh, chief commercial officer (emerging markets) at Biocon Biologics, in a statement. He added that insulin Formulations Insugen-R, Insugen-N, and Insugen-30/70 are manufactured at Biocon Sdn Bhd’s Johor facility and have been approved by the National Pharmaceutical Regulatory Authority of Malaysia (NPRA).

Biocon Biologics, part of Biocon Ltd, has created an insulin Centre of Excellence (CoE) in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal, and rapid insulin products. The insulin facility in Johor is the first and only biopharmaceutical sterile injectable facility in Malaysia to be approved by the US FDA and EMA.

• How to choose the Best Stocks for Intraday F&O trading in India?
• Vedanta Outlook for the Week (May 06, 2024 – May 10, 2024)
• Tata Steel Outlook for the Week (May 06, 2024 – May 10, 2024)
• PFC Outlook for the Week (May 06, 2024 – May 10, 2024)
• Piramal Enterprises Outlook for the Week (May 06, 2024 – May 10, 2024)

Recently, Biocon’s Malaysian-made biosimilar insulin glargine has been approved by the US Food and Drug Administration as “the first interchangeable biosimilar”. Through its scientifically validated human insulin and analogue products manufactured in Malaysia, Biocon Biologics is making these life-saving therapies affordable to patients in many developed markets such as the US, EU, Australia, and the Middle East many emerging markets. Latin America. Biocon Biologics has delivered more than 2.75 billion doses of rh-insulin to patients worldwide.